scispace - formally typeset
Journal

medRxiv

About: medRxiv is an academic journal. The journal publishes majorly in the area(s): Population & Vaccination. Over the lifetime, 26674 publication(s) have been published receiving 156313 citation(s). The journal is also known as: MedArXiv & medRxiv : the preprint server for health sciences.

...read more

Topics: Population, Vaccination, Mental health ...read more
Papers
  More

Open accessPosted ContentDOI: 10.1101/2020.02.06.20020974
Wei-jie Guan1, Zhengyi Ni1, Yu Hu2, Wenhua Liang1  +33 moreInstitutions (12)
09 Feb 2020-medRxiv
Abstract: Background Since December 2019, acute respiratory disease (ARD) due to 2019 novel coronavirus (2019-nCoV) emerged in Wuhan city and rapidly spread throughout China. We sought to delineate the clinical characteristics of these cases. Methods We extracted the data on 1,099 patients with laboratory-confirmed 2019-nCoV ARD from 552 hospitals in 31 provinces/provincial municipalities through January 29th, 2020. Results The median age was 47.0 years, and 41.90% were females. Only 1.18% of patients had a direct contact with wildlife, whereas 31.30% had been to Wuhan and 71.80% had contacted with people from Wuhan. Fever (87.9%) and cough (67.7%) were the most common symptoms. Diarrhea is uncommon. The median incubation period was 3.0 days (range, 0 to 24.0 days). On admission, ground-glass opacity was the typical radiological finding on chest computed tomography (50.00%). Significantly more severe cases were diagnosed by symptoms plus reverse-transcriptase polymerase-chain-reaction without abnormal radiological findings than non-severe cases (23.87% vs. 5.20%, P Conclusions The 2019-nCoV epidemic spreads rapidly by human-to-human transmission. Normal radiologic findings are present among some patients with 2019-nCoV infection. The disease severity (including oxygen saturation, respiratory rate, blood leukocyte/lymphocyte count and chest X-ray/CT manifestations) predict poor clinical outcomes.

...read more

1,239 Citations


Open accessPosted ContentDOI: 10.1101/2020.01.23.20018549
24 Jan 2020-medRxiv
Abstract: Since first identified, the epidemic scale of the recently emerged novel coronavirus (2019-nCoV) in Wuhan, China, has increased rapidly, with cases arising across China and other countries and regions. using a transmission model, we estimate a basic reproductive number of 3.11 (95%CI, 2.39-4.13); 58-76% of transmissions must be prevented to stop increasing; Wuhan case ascertainment of 5.0% (3.6-7.4); 21022 (11090-33490) total infections in Wuhan 1 to 22 January.

...read more

777 Citations


Open accessPosted ContentDOI: 10.1101/2020.12.21.20248640
22 Dec 2020-medRxiv
Abstract: Summary Continued uncontrolled transmission of the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) in many parts of the world is creating the conditions for significant virus evolution. Here, we describe a new SARS-CoV-2 lineage (501Y.V2) characterised by eight lineage-defining mutations in the spike protein, including three at important residues in the receptor-binding domain (K417N, E484K and N501Y) that may have functional significance. This lineage emerged in South Africa after the first epidemic wave in a severely affected metropolitan area, Nelson Mandela Bay, located on the coast of the Eastern Cape Province. This lineage spread rapidly, becoming within weeks the dominant lineage in the Eastern Cape and Western Cape Provinces. Whilst the full significance of the mutations is yet to be determined, the genomic data, showing the rapid displacement of other lineages, suggest that this lineage may be associated with increased transmissibility.

...read more

Topics: Coronavirus (51%)

763 Citations


Open accessPosted ContentDOI: 10.1101/2020.04.05.20054502
Xiao Wu1, Rachel C. Nethery1, M. Benjamin Sabath1, Danielle Braun1  +1 moreInstitutions (1)
27 Apr 2020-medRxiv
Abstract: Objectives United States government scientists estimate that COVID-19 may kill tens of thousands of Americans. Many of the pre-existing conditions that increase the risk of death in those with COVID-19 are the same diseases that are affected by long-term exposure to air pollution. We investigated whether long-term average exposure to fine particulate matter (PM2.5) is associated with an increased risk of COVID-19 death in the United States. Design A nationwide, cross-sectional study using county-level data. Data sources COVID-19 death counts were collected for more than 3,000 counties in the United States (representing 98% of the population) up to April 22, 2020 from Johns Hopkins University, Center for Systems Science and Engineering Coronavirus Resource Center. Main outcome measures We fit negative binomial mixed models using county-level COVID-19 deaths as the outcome and county-level long-term average of PM2.5 as the exposure. In the main analysis, we adjusted by 20 potential confounding factors including population size, age distribution, population density, time since the beginning of the outbreak, time since state’s issuance of stay-at-home order, hospital beds, number of individuals tested, weather, and socioeconomic and behavioral variables such as obesity and smoking. We included a random intercept by state to account for potential correlation in counties within the same state. We conducted more than 68 additional sensitivity analyses. Results We found that an increase of only 1 μg/m3 in PM2.5 is associated with an 8% increase in the COVID-19 death rate (95% confidence interval [CI]: 2%, 15%). The results were statistically significant and robust to secondary and sensitivity analyses. Conclusions A small increase in long-term exposure to PM2.5 leads to a large increase in the COVID-19 death rate. Despite the inherent limitations of the ecological study design, our results underscore the importance of continuing to enforce existing air pollution regulations to protect human health both during and after the COVID-19 crisis. The data and code are publicly available so our analyses can be updated routinely. Summary Box What is already known on this topic Long-term exposure to PM2.5 is linked to many of the comorbidities that have been associated with poor prognosis and death in COVID-19 patients, including cardiovascular and lung disease. PM2.5 exposure is associated with increased risk of severe outcomes in patients with certain infectious respiratory diseases, including influenza, pneumonia, and SARS. Air pollution exposure is known to cause inflammation and cellular damage, and evidence suggests that it may suppress early immune response to infection. What this study adds This is the first nationwide study of the relationship between historical exposure to air pollution exposure and COVID-19 death rate, relying on data from more than 3,000 counties in the United States. The results suggest that long-term exposure to PM2.5 is associated with higher COVID-19 mortality rates, after adjustment for a wide range of socioeconomic, demographic, weather, behavioral, epidemic stage, and healthcare-related confounders. This study relies entirely on publicly available data and fully reproducible, public code to facilitate continued investigation of these relationships by the broader scientific community as the COVID-19 outbreak evolves and more data become available. A small increase in long-term PM2.5 exposure was associated with a substantial increase in the county’s COVID-19 mortality rate up to April 22, 2020.

...read more

Topics: Population (56%), Mortality rate (56%)

705 Citations


Open accessPosted ContentDOI: 10.1101/2020.03.22.20040758
Zhaowei Chen1, Jijia Hu1, Zongwei Zhang1, Shan Shan Jiang1  +5 moreInstitutions (2)
30 Mar 2020-medRxiv
Abstract: Aims Studies have indicated that chloroquine (CQ) shows antagonism against COVID-19 in vitro. However, evidence regarding its effects in patients is limited. This study aims to evaluate the efficacy of hydroxychloroquine (HCQ) in the treatment of patients with COVID-19. Main methods From February 4 to February 28, 2020, 62 patients suffering from COVID-19 were diagnosed and admitted to Renmin Hospital of Wuhan University. All participants were randomized in a parallel-group trial, 31 patients were assigned to receive an additional 5-day HCQ (400 mg/d) treatment, Time to clinical recovery (TTCR), clinical characteristics, and radiological results were assessed at baseline and 5 days after treatment to evaluate the effect of HCQ. Key findings For the 62 COVID-19 patients, 46.8% (29 of 62) were male and 53.2% (33 of 62) were female, the mean age was 44.7 (15.3) years. No difference in the age and sex distribution between the control group and the HCQ group. But for TTCR, the body temperature recovery time and the cough remission time were significantly shortened in the HCQ treatment group. Besides, a larger proportion of patients with improved pneumonia in the HCQ treatment group (80.6%, 25 of 31) compared with the control group (54.8%, 17 of 31). Notably, all 4 patients progressed to severe illness that occurred in the control group. However, there were 2 patients with mild adverse reactions in the HCQ treatment group. Significance Among patients with COVID-19, the use of HCQ could significantly shorten TTCR and promote the absorption of pneumonia. Trial registration URL: https://www.clinicaltrials.gov/. The unique identifier: ChiCTR2000029559.

...read more

  • Table 2: Absorption of pneumonia on chest CT. Abbreviations: HCQ, hydroxychloroquine.
    Table 2: Absorption of pneumonia on chest CT. Abbreviations: HCQ, hydroxychloroquine.
  • Table 1: Characteristics of patients in this trial. a22 patients in the HCQ treatment group,17 patients in the control group with a fever one day before the intervention. b22 patients in the HCQ treatment group,15 patients in the control group with a cough one day before the intervention. Abbreviations: SD, standard deviation; HCQ, hydroxychloroquine; CT, computed tomography.
    Table 1: Characteristics of patients in this trial. a22 patients in the HCQ treatment group,17 patients in the control group with a fever one day before the intervention. b22 patients in the HCQ treatment group,15 patients in the control group with a cough one day before the intervention. Abbreviations: SD, standard deviation; HCQ, hydroxychloroquine; CT, computed tomography.

683 Citations


Performance
Metrics
No. of papers from the Journal in previous years
YearPapers
202111,750
202014,080
2019837
20185
20151
20101

Top Attributes

Show by:

Journal's top 5 most impactful authors

Rosalind M Eggo

35 papers, 1.1K citations

Christl A. Donnelly

32 papers, 893 citations

Claire J. Steves

28 papers, 702 citations

Seiichiro Tateishi

19 papers, 7 citations

Florian Krammer

19 papers, 267 citations

Network Information
Related Journals (5)
BMC Medicine

3K papers, 168.1K citations

87% related
EClinicalMedicine

1.1K papers, 12.7K citations

87% related
bioRxiv

154.3K papers, 439.4K citations

85% related
PLOS Medicine

4.3K papers, 487.4K citations

85% related
BMJ Open

23.3K papers, 316K citations

84% related